

Witness Name: Lynne Kelly

Statement No: WITN3988001

Exhibits: WITN3988002-WITN3988093

Dated: 30 July 2020

EXHIBIT WITN3988056

On 7 Apr 2014, at 12:47, "Thursz, Mark R"

<[GRO-C]> wrote:

Dear Mr [GRO-A]

When I met you in clinic last week you indicated that you might be willing to help lobby for equitable access to antiviral drugs. Charles Gore of the Hepatitis C Trust, Graham Foster a hepatologist from The Royal London Hospital, and I have been lobbying for an early access scheme for Sofosbuvir since December but we appear to be making little headway with NHS England. Mr Qualie, a pharmacist with NHS England suggests in his email below that they are following a process but in reality they are inventing the process and creating new hurdles as they go along.

There is a meeting hosted by the Hep C Trust tomorrow to explain some of the issues to journalists in London. I appreciate that at this short notice you may not be able to make it to London for this meeting. However, if you were willing I would like to be able to put journalists in contact with you. In addition there is likely to be a second press conference immediately after the European Liver Meeting in London this week.

Please let me know if you are happy to be involved and happy to have your contact details passed on to the Hep C Trust

Best wishes

Mark Thursz

Professor Mark Thursz MD FRCP

Head of Section Hepatology & Gastroenterology

St Mary's Hospital Campus Director

10th Floor QEQM Wing

South Warfe Road

London W2 1NY

[GRO-C]

From: GRO-A <GRO-A>
Date: 7 April 2014 15:01:39 BST
To: "Thursz, Mark R" <m.thursz@GRO-C>
Subject: Hepatitis C

Dear Professor Thursz,

Thank you for your email.

Unfortunately, I am unable to attend the meeting tomorrow, however, I do have someone who would be able to attend on my behalf.

I don't know if you are aware, but there is a meeting tomorrow at 2.00pm at the Houses of Parliament regarding Fast Track Funding for Hep C patients, chaired by Alistair Burt MP and attended by other MPs and their constituents.

Lynne Kelly, who is a Trustee of the Haemophilia Society, is attending the meeting at Parliament with my sister-in-law GRO-A GRO-A whose husband (my brother) passed away 4 years ago from HCC through Hep C.

Lynne has been very active in lobbying for fast track funding and I believe has met Charles Gore previously.

As they are both in London, they would be able to attend the meeting, which I believe starts at 10.00am at The King's Fund, Cavendish Square.

Perhaps you would let me know if the meeting might benefit from their attendance.

Kind regards

GRO-A

Prof Thurz

If you have a problem you can contact Mark Thursz on his mobile

GRO-C

Thanks for everything you are doing. If you want to chat, I am on the mobile from 7.30am.

GRO-A

Begin forwarded message:

From: Qualie Malcolm (NHS ENGLAND) [mailto:[malcolm.qualie@gro-c](mailto:malcolm.qualie@gro-c.nhs.uk)]

GRO-C

Sent: 07 April 2014 06:51

To: Charles Gore

Cc: Palmer James (PLYMOUTH HOSPITALS NHS TRUST - RK9); Clinton-Tarestad Pia (NHS ENGLAND)

Subject: RE: Hepatitis C

Charles,

As you know we have a process that we need to follow. This is particularly important given we are a national body and we need to demonstrate fairness in decision making across the population we serve. We have always stated both to the CRGs and Gilead that May is our intended target for a decision and this will still be 6months prior to any NICE decision. I fully appreciate that patients may be waiting for this particular treatment and we will hopefully have a recommendation in the not too distant future.

Regards

Malcolm

Malcolm Qualie

Pharmacy Lead

Specialised Services

NHS England

Tele no: [0115 9515000](tel:0115 9515000) **GRO-C**

Email address: [malcolm.qualie@gro-c](mailto:malcolm.qualie@gro-c.nhs.uk) **GRO-C**

Fosse House, 6 Smith Way, Grove Park, Leic LE19 1SX

From: Charles Gore [mailto:[GRO-C](#)]

Sent: 06 April 2014 23:49

To: Qualie Malcolm (NHS ENGLAND)

Subject: Hepatitis C

Dear Mr Qualie,

We are extremely concerned at the ongoing delay to the approval of the early access programme for people at risk of dying from hepatitis C within the next year. I fully understand that there is a process involved and that the process is new. Nonetheless my understanding is that it has simply come down to a question of cost. Since this is about saving lives which presumably is a top NHS priority it certainly looks from our vantage point that once again hepatitis C patients, coming as they do largely from the bottom socio-economic quintiles, are being de-prioritised. I don't wish to make life difficult for NHSE but our constituency want action. There are a number of media opportunities connected with the International Liver Congress this coming week and we are intending to make use of them and I'm really writing to give you a bit of warning.

Feel free to call [GRO-C](#)

Best wishes

Charles

Charles Gore Chief Executive | [GRO-C](#) | W hepctrust.org.uk

England: 27 Crosby Row, London SE1 3YD | Scotland: 5 Charlotte Square, Edinburgh EH2 4DR

From: Charles Gore [mailto:[GRO-C](#)]

Sent: 07 April 2014 10:34

To: Graham Foster; Thursz, Mark R

Subject: FW: Hepatitis C

Always stated it was May? That's news to me

Charles

Charles Gore Chief Executive | T  F  W hepctrust.org.uk

England: 27 Crosby Row, London SE1 3YD | Scotland: 5 Charlotte Square, Edinburgh EH2 4DR

The Hepatitis C Trust

<image002.jpg> <image003.jpg> <image004.jpg> <image005.jpg>

The Hepatitis C Trust is a Registered Charity, registered in England No 1104279 and Scotland No SCO39914.

The Hepatitis C Trust accepts no responsibility for information, errors or omissions in this email or for its use or misuse. If in doubt, please verify the authenticity of the

contents with the sender. If you are not the addressee indicated in the message (or responsible for delivery of the message to the addressee) you should destroy this message

and kindly notify the sender by reply.

Think before you print..